Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q1 FY24 Earnings Presentation
29 slides from Jubilant Pharmova's earnings presentation, July 2023
Slide 1: Financial Results Quarter Ended June 30, 2023
Financial Results Quarter Ended June 30, 2023 July 2023
Slide 2: Jubilant Pharmova is uniquely positioned to create sustained Shareholder Value
Jubilant Pharmova is uniquely positioned to create sustained Shareholder Value An integrated global Over 5,500 people globally, 6 manufacturing facilities Strong position in Radio- pharmaceuticals and contract including over 2,100 in catering to regulated markets pharmaceuticals, Allergy research co
Slide 3: Business Structure
Business Structure Jubilant Pharmova Limited CDMO Sterile Allergy Proprietary Radiopharma CRDMO Generics Injectables Immunotherapy Novel Drugs Radiopharmaceuticals Radiopharmacies Drug Discovery CDMO - API Services 2
Slide 4: Q1'FY24 – Segment Wise Revenue Split
Q1’FY24 – Segment Wise Revenue Split Allergy Immunotherapy 10% Generics 13% Radiopharma 43% CDMO Sterile Injectables 16% CRDMO 18% 3
Slide 5: Business Snapshot
Business Snapshot • #3 radiopharmaceutical • Leading contract manufacturer • Manufacturing facilities at Roorkee, • Manufacturing facility at manufacturer in the US for Sterile Injectibles India and Salisbury, US Nanjangud, India • Manufacturing facility • Differentiated technologies, viz. • Focus o
Slide 6: High-Quality, World-Class Manufacturing Footprint and Operational Facilities
High-Quality, World-Class Manufacturing Footprint and Operational Facilities Biosys Gr. Noida Facility Spokane, Washington, USA Contract manufacturing of Sterile injectable and Allergy therapy Roorkee, Uttarakhand Generics manufacturing Noida Montreal, Canada Corporate Office Contract Manufact
Slide 7: Financial Highlights Q1'FY24
Financial Highlights Q1’FY24 Jubilant Pharmova Limited
Slide 8: Financial Results Overview Q1'FY24 - Consolidated
Financial Results Overview Q1’FY24 Figures in Rs Crs - Consolidated Particulars Q1'FY23 Q4'FY23 Q1'FY24 Total Revenue 1,452 1,678 1,587 Adjusted Revenue 1 1,382 1,678 1,587 Reported EBITDA 204 224 178 14.0% 13.3% 11.2% Adjusted EBITDA1 137 233 178 9.9% 13.9% 11.2% Impairment of Intangible Assets2 17
Slide 9: Radiopharmaceuticals Highlights
Financial Highlights Radiopharmaceuticals Figures in Rs Crs Particulars Q1'FY23 Q4'FY23 Q1'FY24 Revenue 196 215 204 % of Company Revenue 14% 13% 13% EBITDA 94 100 93 EBITDA Margin (%) 48% 47% 46% 8
Slide 10: Radiopharmaceuticals Key Priorities
Key Priorities Radiopharmaceuticals • Maintain leadership position in stable high margin core portfolio in North America, e.g., lung functional imaging and thyroid targeted radiotherapeutics • Innovation leader in PET cardiac imaging through proprietary RUBY-FILL (best in class cardiac imaging produ
Slide 11: Radiopharmacies Highlights
Financial Highlights Radiopharmacies Figures in Rs Crs Particulars Q1'FY23 Q4'FY23 Q1'FY24 Revenue 396 475 487 % of Company Revenue 27% 28% 31% EBITDA (21) (4) 1.8 EBITDA Margin (%) (5%) (1%) 0.4% 10
Slide 12: Radiopharmacies Key Priorities
Key Priorities Radiopharmacies • Accelerate sales of high growth new products, e.g., Ga-PSMA, and to further gain market share in existing SPECT products • Maintain current momentum of strong growth in merchant sales • Leverage existing cyclotrons to capture share of PET product growth • Additionall
Slide 13: Allergy Immunotherapy Highlights
Financial Highlights Allergy Immunotherapy Figures in Rs Crs Particulars Particulars Q1'FY23 Q1'FY23 Q4'FY23 Q4'FY23 Q1'FY24 Q1'FY24 Revenue Revenue 130 130 170 170 151 151 % % of of Company Company Revenue Revenue 9% 9% 10% 10% 10% 10% EBITDA EBITDA 44 44 55 55 50 50 EBITDA EBITDA Margin Margin (%)
Slide 14: Allergy Immunotherapy Key Priorities
Key Priorities Allergy Immunotherapy • #2 player in US Sub-Cutaneous Immunotherapy market (Venom and Non-Venom) of >$200M. High barriers to entry as products are branded biologicals with regulatory approvals grandfathered in • Further strengthen the prescriber base for Venom immunotherapy in the US
Slide 15: CDMO Sterile Injectables Highlights
Financial Highlights CDMO Sterile Injectables Figures in Rs Crs Particulars Q1'FY23 Q4'FY23 Q1'FY24 Revenue 263 321 254 % of Company Revenue 18% 19% 16% EBITDA 132 86 41 EBITDA Margin (%) 50% 27% 16% Adjusted Revenue 193 321 254 Adjusted EBITDA 66 86 41 Adjusted EBITDA Margin 34% 27% 16% 1. Adjusted
Slide 16: CDMO Sterile Injectables Key Priorities
Key Priorities CDMO Sterile Injectables • Global Fill and Finish Sterile Injectable markets of USD 13Bn, with double digit growth rate projected over next 5 years • Focus is on-time and at-cost execution of USD 370Mn capacity expansion in Spokane and Montreal, to double the CMO capacity over next 5+
Slide 17: Generics Highlights
Financial Highlights Generics Figures in Rs Crs Particulars Q1'FY23 Q4'FY23 Q1'FY24 Revenue 178 199 202 % of Company Revenue 12% 12% 13% EBITDA (74) (39) (21) EBITDA Margin (%) (41%) (20%) (10%) Adjusted Revenue 178 199 202 Adjusted EBITDA (74) (30) (21) Adjusted EBITDA Margin (41%) (15%) (10%) 1. A
Slide 18: Generics Key Priorities
Key Priorities Generics • Continue quality improvement initiatives and engagement with the US FDA for resolution of Import Alert at the Roorkee facility. • Salisbury site is compliant with US FDA. Roorkee site is compliant with other key non-US markets, e.g., MHRA, Japan, South Africa, Canada. • Foc
Slide 19: Drug Discovery Services Highlights
Financial Highlights Drug Discovery Services Figures in Rs Crs Particulars Q1'FY23 Q4'FY23 Q1'FY24 Revenue 118 131 103 % of Company Revenue 8% 8% 7% EBITDA 39 35 22 EBITDA Margin (%) 33% 26% 21% 18
Slide 20: Drug Discovery Services Key Priorities
Key Priorities Drug Discovery Services • Leverage state of the art infrastructure and differentiated technical know-how, e.g., Integrated Drug Discovery, DMPK to drive new customer acquisitions in drug discovery • Continue to invest in capabilities for improving productivity, speeding up time to mar
Slide 21: CDMO - API Highlights
Financial Highlights CDMO - API Figures in Rs Crs Particulars Q1'FY23 Q4'FY23 Q1'FY24 Revenue 162 163 177 % of Company Revenue 11% 10% 11% EBITDA 6 12 13 EBITDA Margin (%) 4% 7% 7% VAI : Voluntary Action Indicated 20
Slide 22: CDMO - API Key Priorities
Key Priorities CDMO - API • In March 2023, the API plant at Nanjangud saw reversal of OAI status to compliant VAI status from USFDA, driven by Quality Improvement Initiatives at site. • Going forward, focus is to drive higher capacity utilization including through launch of new products and by acqui
Slide 23: Proprietary Novel Drugs Highlights
Financial Highlights Proprietary Novel Drugs Figures in Rs Crs Particulars Q1'FY23 Q4'FY23 Q1'FY24 Revenue 4 0 0 EBITDA (7) (10) (10) 22
Slide 24: Proprietary Novel Drugs Key Highlights & Priorities
Key Highlights & Priorities Proprietary Novel Drugs • Clinical stage precision therapeutics business advancing potent and selective small molecules to address unmet medical needs in oncology and autoimmune diseases • Wholly owned assets; opportunities to explore institutional funding, as well as max
Slide 25: Business Enablers
Business Enablers Jubilant Pharmova Limited 24
Slide 26: Sustainability continues to be an important focus area for us
Sustainability continues to be an important focus area for us Participated in S&P DJSI Assessment: - Achieved 94 percentile in the Global Pharmaceutical Industry - Among the top 6% companies - Received Gold Rating globally - Among top 4 Indian Pharma - Achieved 92 percentile (Score companies in ESG
Slide 27: Annexure
Annexure Jubilant Pharmova Limited
Slide 28: Segment Financial Results Overview | Consolidated
Segment Financial Results Overview | Consolidated Figures in Rs Crs Segment Revenue Q1'FY23 Q4'FY23 Q1'FY24 FY23 1.Radiopharma 592 689 691 2,552 Radiopharmaceuticals 196 215 204 872 Radiopharmacies 396 475 487 1,681 2. Allergy Immunotherapy 130 170 151 603 3. CDMO Sterile Injectables 263 321 254 1,1
Slide 29: For more information
For more information For Investors: Vineet V Mayer Siddharth Rangnekar Jubilant Pharmova Limited CDR India Ph: +91 120 436 1103 Ph: +91 +91 9769919966 E-mail: Vineet.mayer@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1062 Madison Public Relations